As mentioned above, the worst performer this week was my biggest holding
OPTI:Optibiotix, dropping 11%. The volatility of this share price is massively frustrating. I know I should relax and be patient, as rewards will be reaped in the future, but it's hard when you are sitting on such big paper losses.
SBTX:SkinBioTherapeutics dropped 10% in sympathy I think, with my SIPP holding 19% down and my ISA holding 40% down on purchase price. There should be a second big deal announced soon, and hopefully this one will promise revenues a bit sooner than the last. Again, as a patient investor it shouldn't be an issue that income is 2 years away. I should just be buying more while they are cheap.
JLP:Jubilee Metals had a good week, climbing 5% and getting to within 3% of being in profit. It's been a long wait, but hope has really been kindled for these.
RDT:Rosslyn Data climbed an impressive 8%, but they are still 67% down and I fear a long way from getting back into the black. This is a very small holding for me though.
IKA:Ilika march forward another 12% and are only down by commission now. If someone had asked me to list the order of the shares that I would expect to return to the black next, this one would have been well down the list.
Share of the week is TRMR:Tremor, which climbed a whopping 16% but is still 32% down in my trading account. I think there's a good chance these are going to recover now.
Back into deep trouble
The only ray of sunshine is we're still above the trend line.
The ISA and share portfolios look like this
| Weekly Change | |||
| Cash | £11.99 | +£0 | |
| Portfolio cost | £57,768.95 | +£0 | |
| Portfolio sell value (bid price-commission) | £37,991.43 | (-34.2%) | -£3,885.76 |
| Potential profits | £0 | +£0 | |
| Yr 5 Dividends | £0.63 | +£0 | |
| Yr 5 Profit from sales | £-167.28 | +£0 | |
| Yr 5 Average monthly cash profit | -£33.48 | (-0.7%) | +£1.45 |
| Total Dividends | £1,342.93 | +£0 | |
| Total Profit from sales | £20,224.13 | +£0 | |
| Average monthly cash profit | £398.90 | (8.3%) | -£1.73 |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Performance/Injection | 12.8% | -0.2% | |
| Compound performance | 57% | +0% |
Huge drop, nearly all of which is down to OPTI:Optibiotix.
Only just above the injection line.
Here's the SIPP after week 216
| Weekly Change | ||||
| Cash | £74.75 | +£0 | ||
| Portfolio cost | £46,995.31 | +£0 | ||
| Portfolio sell value (bid price - commission) |
£34,540.76 | (-26.5%) | -£3,575.41 | |
| Potential profits | £782.97 | +£30.00 | ||
| Yr 5 Dividends | £0 | +£0 | ||
| Yr 5 Interest | £0.02 | +£0 | ||
| Yr 5 Profit from sales | £0 | +£0 | ||
| Yr 5 Average monthly cash profit | -£15.48 | (-0.4%) | +£2.21 | |
| Total Dividends | £1,899.24 | +£0 | ||
| Total Interest | £0.18 | +£0 | ||
| Total Profit from sales | £12,549.10 | +£0 | ||
| Average monthly cash profit | £280.40 | (7.2%) | -£1.30 | |
| (Sold stocks profit + Dividends - Fees / Months) | ||||
| Performance/Injection | 11.3% | +0% | ||
| Compound performance | 47% | +0% |
Same OPTI:Optibiotix problem as the ISA, but CAML:Central Asia Metals climbed a little to raise potential profits by £30
Still a healthy buffer here.
Here's the trading account after week 182
| Weekly Change | |||
| Cash | £48.24 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,363.30 | (-41.3%) | +£82.07 |
| Potential profits | £0 | +£0 | |
| Year 4 Dividends | £13.20 | +£0 | |
| Year 4 Profit | £0 | +£0 | |
| Yr 4 Average monthly cash profit | £2.20 | (1.1%) | -£0.09 |
| Dividends | £47.92 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£0.39 | (-0.2%) | +£0 |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Performance/Injection | -0.2% | +0% | |
| Compound performance | -1% | +0% |
Nice week, with lots of rises, but still no prospect of a sale.
It's been going in the right direction for a few weeks now.
I'm reasonably hopeful this lot will turn around.
That's it - no more for this catch-up week.
No comments:
Post a Comment